Abbott Laboratories


  • Abbott Labs profit beats Street estimates Thursday, 29 Jan 2015 | 7:59 AM ET

    Jan 29- Abbott Laboratories reported a better-than-expected quarterly profit, helped by re-introduction in China and Vietnam of pediatric milk formula brands. The company's net earnings rose to $905 million, or 59 cents per share, in the fourth quarter from $589 million, or 37 cents per share, a year earlier. Excluding special items, Abbott earned 71 cents per...

  • Defendants in California and Massachusetts have sought to take advantage of a December ruling from the 2nd U.S. Circuit Court of Appeals in New York that narrowed the definition of insider trading, making it harder for prosecutors to pursue their cases. The challenges raise the possibility that the 2nd Circuit decision, legally binding only in New York,...

  • NEW YORK, Jan 21- For more than eight years, Johnson& Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial- and ultimately ill-fated- bidding war for device maker Guidant. J&J is seeking more than $7.2 billion in damages and interest from Boston Scientific as Guidant's successor, an amount that one...

  • Early movers: SNDK, HLT, MET, WWW, AAPL & more Tuesday, 13 Jan 2015 | 7:53 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.

  • It's all about oil, the euro and a strong dollar Monday, 5 Jan 2015 | 10:43 AM ET
    A man walks by a euro sign light installation in Vilnius, Lithuania, on Dec. 31, 2014.

    If the weak euro, strong dollar and cheap oil persist, these commodities and stocks will predictably take a hit.

  • How to play the third-quarter GDP beat Tuesday, 23 Dec 2014 | 12:32 PM ET
    Traders on the floor of the New York Stock Exchange, December 1, 2014.

    Investors can find value in blue-chip health-care stocks and old-world tech names, and should stick to U.S. equities, Chad Morganlander said.

  • Early Movers: WAG, GMCR, CHK, JPM & more Tuesday, 23 Dec 2014 | 8:08 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Dec 22- The U.S. Justice Department has filed a complaint against Omnicare Inc, alleging that the largest U.S. provider of pharmacy services to the elderly received millions of dollars in kickbacks from Abbott Laboratories. Omnicare received the kickbacks for recommending Abbott's prescription drug, Depakote, for epilepsy in dementia patients in nursing...

  • NEW YORK/ SANTIAGO- A former board member of Chile's CFR Pharmaceuticals SA was charged on Monday by U.S. regulators with insider trading on information regarding Abbott Laboratories' $2.9 billion acquisition of CFR earlier this year. Hurtado earned nearly $500,000 in profits, according to the SEC. According to the SEC, Bilbao first learned of Abbott's...

  • Midday Movers: Exxon Mobil, Morgan Stanley & more Friday, 12 Dec 2014 | 1:02 PM ET
    New York Stock Exchange NYSE

    Some of Friday's midday movers:

  • Your first trade for Wednesday Tuesday, 2 Dec 2014 | 6:36 PM ET
    Fast Money Final Trade: FXC, EWZ, M, TLT

    The "Fast Money" traders give their final trades of the day.

  • SHANGHAI/ LONDON, Dec 3- Chinese infant formula giant Beingmate prints Irish clovers on its flagship product as it seeks to assure Chinese parents of its European sourcing after a safety scare involving the world's biggest milk powder exporter New Zealand. Though the scare turned out to be false, it prompted formula firms to reduce supplies from New Zealand and...

  • FACTBOX-Recent tax inversion proposals Tuesday, 25 Nov 2014 | 1:19 PM ET

    Medical technology company Medtronic Inc said on Nov. 18 that its plan to acquire and adopt the tax domicile of Ireland's Covidien Plc was on track to close in 2015.. High-tech manufacturer Applied Materials Inc plans to buy Japanese rival Tokyo Electron Ltd and reincorporate in the Netherlands. Burger King Worldwide Inc plans to acquire Canadian coffee and...

  • SEC director with big stock holdings stirs debate Friday, 21 Nov 2014 | 8:00 AM ET

    The man who runs the office that reviews companies' books at the U.S. SEC reported stock holdings of between $2 million and $6 million last year.

  • WASHINGTON, Nov 21- Keith Higgins, who runs the office that reviews public companies' books at the U.S. Securities and Exchange Commission, reported stock holdings worth between about $2 million and $6 million last year and the sale of stocks throughout 2014, according to SEC disclosures viewed by Reuters. Since the beginning of the year, he has reported about 60...

  • NEW YORK, Nov 19- Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp, Johnson& Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday. A federal court judge in New York will hear the case without a jury and decide whether Guidant, through its successor Boston Scientific, should be...

  • Midday movers: Allergan, CarMax, CBS & more Monday, 17 Nov 2014 | 1:03 PM ET
    NYSE New York Stock Exchange traders markets

    Some of Monday's midday movers:

  • WASHINGTON, Nov 12- Republicans in the U.S. Congress will soon move to kill a medical device tax imposed less than two years ago under President Barack Obama's healthcare law, congressional aides and analysts said on Wednesday. Though no full-scale repeal of Obamacare is expected, even with the Senate now under Republican control, the move against the tax is part...

  • Republican knives out for Obama's medical devices tax Wednesday, 12 Nov 2014 | 5:25 PM ET

    Last week's elections will elevate Republican Senator Orrin Hatch, a long-standing opponent of the tax, to the chairmanship of the tax-writing finance committee in the Senate. Though no full-scale repeal of Obamacare is expected, even with the Senate under Republican control, the move against the device tax is part of efforts to chip away at the law.

  • AbbVie: Strong results lessen need for big deal Friday, 31 Oct 2014 | 12:46 PM ET
    Pharmaceuticals health care drugs cost

    AbbVie reported strong earnings on demand for its Humira drug and said it could deliver strong long-term growth without another big merger bid.